Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 6:2:6609.
doi: 10.1186/1757-1626-0002-0000006609.

Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series

Nikolay Tzaribachev  1 , Ina Koetter, Jasmin B Kuemmerle-Deschner, Joerg Schedel
Affiliations

Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series

Nikolay Tzaribachev et al. Cases J. .

Abstract

Introduction: To report on efficacy, tolerability and safety of rituximab in children with refractory autoimmune diseases.

Case presentation: Five patients (juvenile dermatomyositis, Wegener's granulomatosis, systemic lupus erythematosus, myasthenia gravis and multiple sclerosis with systemic lupus erythematosus) were treated with rituximab and followed for a median time of 2.5 years. Two patients achieved remission (systemic lupus erythematosus, Wegener's granulomatosis). Three patients had a refractory disease course and underwent autologous stem cell transplantation. Of those, two achieved remission (juvenile dermatomyositis, myasthenia gravis), one died of complications after transplantation (multiple sclerosis/systemic lupus erythematosus). No severe adverse events occurred.

Conclusion: Efficacy of rituximab was variable ranging from complete remission to inefficacy. Treatment was safe.

PubMed Disclaimer

Figures

Figure 1
Figure 1
B-cell depletion in patients 1 (JDM), 2 (WG), 4 (SLE/MG) and 5 (MS/SLE). No clear correlation between B-cell recurrence and disease flares can be seen. In patient 4 (SLE/MG) B-cells were reduced below normal levels due to treatment with cyclophosphamide. JDM, juvenile dermatomyositis; WG, Wegener's granulomatosis; SLE, systemic lupus erythematodes; MG, myasthenia gravis; MS, multiple sclerosis; ASCT, autologous stem cell transplantation; RTX, rituximab.
See this image and copyright information in PMC

References

    1. O'Neill SK, Shlomchik MJ, Glant TT, Cao Y, Doodes PD, Finnegan A. 22, Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol. 2005;174:3781–3788. - PubMed
    1. Lund FE, Garvy BA, Randell TD, Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun. 2005;8:25–54. full_text. - PubMed
    1. Emery P, Furst DE, Ferraccioli G, Udell J, van Vollenhoven RF, Rowe K. Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2006;65:58.
    1. Binstadt BA, Caldas AM, Turvey SE, Stone KD, Weinstein HJ, Jackson J, Fuhlbrigge RC, Sundel RP. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr. 2003;143:598–604. doi: 10.1067/S0022-3476(03)00382-2. - DOI - PubMed
    1. Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2008;23:413–419. doi: 10.1007/s00467-007-0694-9. - DOI - PMC - PubMed

LinkOut - more resources